Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Trial record 2 of 220 for:    eden

A Retrospective Chart Review Study of Gene-Eden-VIR/Novirin

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
The Center for the Biology of Chronic Disease
ClinicalTrials.gov Identifier:
NCT02715752
First received: March 17, 2016
Last updated: April 24, 2016
Last verified: April 2016
  Purpose
This study measured the changes in health-related complaints by analyzing charts of individuals, who are infected with a latent virus, who have used Gene-Eden-VIR/Novirin.

Condition Intervention
Herpes Simplex Infections
Human Papillomavirus
Epstein-Barr Virus Infections
Varicella-zoster Virus Infection
Cytomegalovirus Infections
Dietary Supplement: Gene-Eden-VIR/Novirin

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: A Retrospective Chart Review Study of Gene-Eden-VIR/Novirin

Resource links provided by NLM:


Further study details as provided by The Center for the Biology of Chronic Disease:

Primary Outcome Measures:
  • frequency of symptoms [ Time Frame: one year ] [ Designated as safety issue: No ]
  • duration of symptoms [ Time Frame: one year ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • time to first recurrence [ Time Frame: one year ] [ Designated as safety issue: No ]

Enrollment: 1000
Study Start Date: January 2016
Study Completion Date: March 2016
Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Herpes Simplex Virus Infection
Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
Dietary Supplement: Gene-Eden-VIR/Novirin
Human Papillomavirus Infection
Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
Dietary Supplement: Gene-Eden-VIR/Novirin
Epstein-Barr Virus Infection
Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
Dietary Supplement: Gene-Eden-VIR/Novirin
Cytomegalovirus Infection
Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
Dietary Supplement: Gene-Eden-VIR/Novirin
Varicella Zoster Virus Infection
Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
Dietary Supplement: Gene-Eden-VIR/Novirin

Detailed Description:
The medical community calls the movement from severe to mild disease and from mild to normal health, 'relieving symptoms', and the interventions that cause such movement, drugs, medications, or therapies. The alternative community calls the movement from normal health to superior health, 'boosting health' (or boosting the immune system, or improving your sex drive, or boosting any another well functioning physiological system), and the interventions that cause such movement, natural remedies, dietary supplements, complementary treatments, etc. In general, these interventions aim to achieve superior performance of a normal human body. Of course, boosting the body's normal performance improves many of its capabilities, such as higher resistance to diseases, faster recovery from fatigue, better mental concentration, etc. Each movement presents different objectives. Relieving symptoms represents the ability of an intervention to reduce the frequency, duration, and severity of a disease. In contrast, boosting health represents the ability of an intervention to increase the frequency, duration, and quality of a person's health. In the current study, the investigators would like to measure the changes in health-related complaints by analyzing charts of individuals, who are infected with latent virus, and who have used Gene-Eden-VIR/Novirin.
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Men and women ages greater than 18 years old
Criteria

Inclusion Criteria:

  • Latent viral infection with either HSV, HPV, VZV, EBV, or CMV
  • Taking Gene-Eden-VIR/Novirin

Exclusion Criteria:

  • Use of other antiviral treatments
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02715752

Locations
United States, New York
The Center for the Biology of Chronic Disease
Valley Cottage, New York, United States, 10989
Sponsors and Collaborators
The Center for the Biology of Chronic Disease
  More Information

Responsible Party: The Center for the Biology of Chronic Disease
ClinicalTrials.gov Identifier: NCT02715752     History of Changes
Other Study ID Numbers: 022015 
Study First Received: March 17, 2016
Last Updated: April 24, 2016
Health Authority: United States: Institutional Review Board
Individual Participant Data  
Plan to Share IPD: Undecided

Additional relevant MeSH terms:
Infection
Communicable Diseases
Virus Diseases
Herpes Simplex
Chickenpox
Cytomegalovirus Infections
Herpes Zoster
Epstein-Barr Virus Infections
Herpesviridae Infections
DNA Virus Infections
Skin Diseases, Viral
Skin Diseases, Infectious
Skin Diseases
Tumor Virus Infections

ClinicalTrials.gov processed this record on September 23, 2016